{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T17:45:23Z","timestamp":1774633523277,"version":"3.50.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH\/NIAID","award":["1R01AI138986-01"],"award-info":[{"award-number":["1R01AI138986-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The widespread emergence of antibiotic resistance including MDR in Gram-negative bacterial pathogens poses a critical challenge to the current antimicrobial armamentarium.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To create a novel drug\u2013Fc conjugate (DFC) that can be delivered at sustained and prolonged levels while simultaneously activating the host immune response to combat MDR Gram-negative infections.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The Cloudbreak\u2122 platform was used to develop DFCs consisting of a targeting moiety (TM) (a polymyxin-derived dimer) attached via a non-cleavable linker to an effector moiety (EM) (the Fc domain of human IgG1). In vitro activities of the DFCs were assessed by MIC testing. Neutropenic mouse models of thigh infection, septicaemia and pneumonia were used to evaluate in vivo efficacy. Pharmacokinetics were evaluated in mice and cynomolgus monkeys.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A single prophylactic dose of our lead DFC, CTC-177, resulted in significantly decreased bacterial burdens and reduced inflammation comparable to daily treatment with colistin in septicaemia and pneumonia mouse models. Furthermore, CTC-177 prophylaxis was able to restore colistin efficacy in colistin-resistant septicaemia, reducing bacterial burdens beyond the limit of detection. Finally, CTC-177 displayed a long terminal half-life of over 24 and 65 h in mice and cynomolgus monkeys, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These data support the continued development of Cloudbreak\u2122 DFCs as broad-spectrum prophylactic agents against Gram-negative infections.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlae100","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:57:32Z","timestamp":1722041852000},"source":"Crossref","is-referenced-by-count":1,"title":["CTC-177, a novel drug\u2013Fc conjugate, shows promise as an immunoprophylactic agent against multidrug-resistant Gram-negative bacterial infections"],"prefix":"10.1093","volume":"6","author":[{"given":"Arianne","family":"Lovey","sequence":"first","affiliation":[{"name":"Center for Discovery and Innovation, Hackensack Meridian Health , Nutley, NJ 07110 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Lee","sequence":"additional","affiliation":[{"name":"Center for Discovery and Innovation, Hackensack Meridian Health , Nutley, NJ 07110 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Yu","sequence":"additional","affiliation":[{"name":"Center for Discovery and Innovation, Hackensack Meridian Health , Nutley, NJ 07110 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mila","family":"Krel","sequence":"additional","affiliation":[{"name":"Center for Discovery and Innovation, Hackensack Meridian Health , Nutley, NJ 07110 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Discovery and Innovation, Hackensack Meridian Health , Nutley, NJ 07110 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padmaja","family":"Paderu","sequence":"additional","affiliation":[{"name":"Center for Discovery and Innovation, Hackensack Meridian Health , Nutley, NJ 07110 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Brady","sequence":"additional","affiliation":[{"name":"Departments of Medicinal Chemistry and Protein Chemistry, Cidara Therapeutics, Inc. , San Diego, CA 92121 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grayson","family":"Hough","sequence":"additional","affiliation":[{"name":"Departments of Medicinal Chemistry and Protein Chemistry, Cidara Therapeutics, Inc. , San Diego, CA 92121 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiping","family":"Zhao","sequence":"additional","affiliation":[{"name":"Departments of Medicinal Chemistry and Protein Chemistry, Cidara Therapeutics, Inc. , San Diego, CA 92121 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M","family":"Balkovec","sequence":"additional","affiliation":[{"name":"Departments of Medicinal Chemistry and Protein Chemistry, Cidara Therapeutics, Inc. , San Diego, CA 92121 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S","family":"Perlin","sequence":"additional","affiliation":[{"name":"Center for Discovery and Innovation, Hackensack Meridian Health , Nutley, NJ 07110 , USA"},{"name":"Hackensack Meridian School of Medicine , Hackensack Meridian Health, Nutley, NJ 07110 , USA"},{"name":"Lombardi Comprehensive Cancer Center , Georgetown University, Washington, DC 20057 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2664-2795","authenticated-orcid":false,"given":"Yanan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Center for Discovery and Innovation, Hackensack Meridian Health , Nutley, NJ 07110 , USA"},{"name":"Hackensack Meridian School of Medicine , Hackensack Meridian Health, Nutley, NJ 07110 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"2024083008114346900_dlae100-B1","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.mpaic.2015.09.010","article-title":"Nosocomial infections in the intensive care unit","volume":"16","author":"Trubiano","year":"2015","journal-title":"Anaesth Intensive Care Med"},{"key":"2024083008114346900_dlae100-B2","author":"CDC"},{"key":"2024083008114346900_dlae100-B3","author":"CDC"},{"key":"2024083008114346900_dlae100-B4","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/529198","article-title":"Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options","volume":"46","author":"Eliopoulos","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2024083008114346900_dlae100-B5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3390\/pathogens3030743","article-title":"Antibiotic resistance related to biofilm formation in Klebsiella pneumoniae","volume":"3","author":"Vuotto","year":"2014","journal-title":"Pathogens"},{"key":"2024083008114346900_dlae100-B6","doi-asserted-by":"crossref","first-page":"30155","DOI":"10.2807\/1560-7917.ES.2016.21.9.30155","article-title":"Plasmid-mediated colistin resistance (mcr-1 gene): three months later, the story unfolds","volume":"21","author":"Skov","year":"2016","journal-title":"Euro Surveill"},{"key":"2024083008114346900_dlae100-B7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fcimb.2017.00039","article-title":"Pseudomonas aeruginosa lifestyle: a paradigm for adaptation, survival, and persistence","volume":"7","author":"Moradali","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"2024083008114346900_dlae100-B8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/femsre\/fux013","article-title":"Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance","volume":"41","author":"Navon-Venezia","year":"2017","journal-title":"FEMS Microbiol Rev"},{"key":"2024083008114346900_dlae100-B9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/CMR.00058-16","article-title":"Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges","volume":"30","author":"Wong","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"2024083008114346900_dlae100-B10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnol Adv"},{"key":"2024083008114346900_dlae100-B11","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s13054-014-0596-8","article-title":"Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study","volume":"18","author":"Zilberberg","year":"2014","journal-title":"Crit Care"},{"key":"2024083008114346900_dlae100-B12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fmed.2019.00074","article-title":"Treatment of infections due to MDR Gram-negative bacteria","volume":"6","author":"Bassetti","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"2024083008114346900_dlae100-B13","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1021\/acsinfecdis.3c00575","article-title":"Rational design of a potent antimicrobial peptide based on the active region of a gecko cathelicidin","volume":"10","author":"Cai","year":"2024","journal-title":"ACS Infect Dis"},{"key":"2024083008114346900_dlae100-B14","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.cmi.2022.01.006","article-title":"The effects of different doses of inhaled bacteriophage therapy for Pseudomonas aeruginosa pulmonary infections in mice","volume":"28","author":"Chang","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2024083008114346900_dlae100-B15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.24976\/Discov.Med.202436181.33","article-title":"rgpA-Engineered\/functionalized DNA vaccine as a novel prophylactic vaccination to prevent Porphyromonas gingivalis-induced periodontitis: an in vivo study","volume":"36","author":"Fan","year":"2024","journal-title":"Discov Med"},{"key":"2024083008114346900_dlae100-B16","doi-asserted-by":"crossref","first-page":"e0098521","DOI":"10.1128\/AAC.00985-21","article-title":"Development of novel immunoprophylactic agents against multidrug-resistant Gram-negative bacterial infections","volume":"65","author":"Lovey","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024083008114346900_dlae100-B17","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1469-0691.2005.01227.x","article-title":"Clinical impact and pathogenicity of Acinetobacter","volume":"11","author":"Joly-Guillou","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"2024083008114346900_dlae100-B18","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1164\/rccm.201102-0349OC","article-title":"High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia","volume":"184","author":"Chung","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2024083008114346900_dlae100-B19","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1128\/AAC.01520-13","article-title":"Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes","volume":"57","author":"Chopra","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2024083008114346900_dlae100-B20","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1128\/AAC.02441-14","article-title":"Risk factors and outcomes for patients with bloodstream infection due to Acinetobacter baumannii-calcoaceticus complex","volume":"58","author":"Chopra","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024083008114346900_dlae100-B21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.cmi.2015.12.010","article-title":"Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia","volume":"22","author":"Freire","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2024083008114346900_dlae100-B22","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1073\/pnas.61.4.1414","article-title":"Amino acid sequence of the Fc region of a human gamma G-immunoglobulin","volume":"61","author":"Rutishauser","year":"1968","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024083008114346900_dlae100-B23","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Tenth Edition: M07","author":"CLSI","year":"2015"},{"issue":"Suppl C","key":"2024083008114346900_dlae100-B24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/27.suppl_C.29","article-title":"Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections","volume":"27","author":"Craig","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"2024083008114346900_dlae100-B25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2024083008114346900_dlae100-B26","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/jac\/dkn530","article-title":"Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa","volume":"63","author":"Aoki","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2024083008114346900_dlae100-B27","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood.V74.5.1704.1704","article-title":"Increased plasma levels of interleukin-6 in sepsis","volume":"74","author":"Hack","year":"1989","journal-title":"Blood"},{"key":"2024083008114346900_dlae100-B28","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S0022-3476(05)82476-X","article-title":"Correlation of plasma cytokine elevations with mortality rate in children with sepsis","volume":"120","author":"Sullivan","year":"1992","journal-title":"J Pediatr"},{"key":"2024083008114346900_dlae100-B29","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1186\/s12879-019-4618-7","article-title":"Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions","volume":"19","author":"Song","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2024083008114346900_dlae100-B30","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.4049\/jimmunol.1002971","article-title":"IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3","volume":"186","author":"Greenhill","year":"2011","journal-title":"J Immunol"},{"key":"2024083008114346900_dlae100-B31","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/0140-6736(91)91452-Z","article-title":"Septic shock: pathogenesis","volume":"338","author":"Glauser","year":"1991","journal-title":"Lancet"},{"key":"2024083008114346900_dlae100-B32","doi-asserted-by":"crossref","first-page":"156006","DOI":"10.1016\/j.cyto.2022.156006","article-title":"Proinflammatory cytokines levels in sepsis and healthy volunteers, and tumor necrosis factor-alpha associated sepsis mortality: a systematic review and meta-analysis","volume":"158","author":"Gharamti","year":"2022","journal-title":"Cytokine"},{"key":"2024083008114346900_dlae100-B33","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1172\/JCI1020","article-title":"MIP-1alpha as a critical macrophage chemoattractant in murine wound repair","volume":"101","author":"DiPietro","year":"1998","journal-title":"J Clin Invest"},{"key":"2024083008114346900_dlae100-B34","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.medin.2012.09.008","article-title":"Role of circulating soluble chemokines in septic shock","volume":"37","author":"de Pablo","year":"2013","journal-title":"Med Intensiva"},{"key":"2024083008114346900_dlae100-B35","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/femsre\/fuz014","article-title":"Antibiotic resistance breakers: current approaches and future directions","volume":"43","author":"Laws","year":"2019","journal-title":"FEMS Microbiol Rev"},{"key":"2024083008114346900_dlae100-B36","doi-asserted-by":"crossref","first-page":"835677","DOI":"10.3389\/fmicb.2022.835677","article-title":"The use of antibody-antibiotic conjugates to fight bacterial infections","volume":"13","author":"Cavaco","year":"2022","journal-title":"Front Microbiol"},{"key":"2024083008114346900_dlae100-B37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.molmed.2016.12.008","article-title":"Antibody\u2013antibiotic conjugates: a novel therapeutic platform against bacterial infections","volume":"23","author":"Mariathasan","year":"2017","journal-title":"Trends Mol Med"},{"key":"2024083008114346900_dlae100-B38","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.chest.2020.03.087","article-title":"A systematic review of the effect of delayed appropriate antibiotic treatment on the outcomes of patients with severe bacterial infections","volume":"158","author":"Zasowski","year":"2020","journal-title":"Chest"},{"key":"2024083008114346900_dlae100-B39","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3855\/jidc.7203","article-title":"Impact of colistin-initiation delay on mortality of ventilator-associated pneumonia caused by A. baumannii","volume":"10","author":"Samrah","year":"2016","journal-title":"J Infect Dev Ctries"},{"key":"2024083008114346900_dlae100-B40","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1164\/ajrccm.165.7.2105078","article-title":"Ventilator-associated pneumonia","volume":"165","author":"Chastre","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2024083008114346900_dlae100-B41","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/00003246-200206000-00013","article-title":"Aminoglycoside and glycopeptide renal toxicity in intensive care patients studied by proton magnetic resonance spectroscopy of urine","volume":"30","author":"Le Moyec","year":"2002","journal-title":"Crit Care Med"},{"key":"2024083008114346900_dlae100-B42","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10156-013-0549-1","article-title":"Impact of the initiation time of colistin treatment for Acinetobacter infections","volume":"19","author":"Tigen","year":"2013","journal-title":"J Infect Chemother"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/6\/4\/dlae100\/58875653\/dlae100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/6\/4\/dlae100\/58875653\/dlae100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T12:54:48Z","timestamp":1725022488000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlae100\/7721434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlae100","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,7,3]]},"article-number":"dlae100"}}